On Friday 26 May, the Minister of Health and Care in Norway, Ingvild Kjerkol, received a report from the regional health undertakings with national key figures and a mention of the best research and innovation projects in the Norwegian hospitals in 2022.

This is the tenth report of its kind, and Lytix Biopharma’s Phase I international multicenter study with LTX-315 (“Safety, antitumor efficacy and T-cell response in a dose-escalating study of oncolytic peptide LTX-315 in patients with solid tumors") was among the mentioned projects.

Read about the study here